Fluvoxamine

Generic Name: Fluvoxamine

Brand Names: Luvox

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁F_₃N_₂O_₂

CAS Number: 54739-18-3

Unique Ingredient Identifier: O4L1XPO44W

Background: Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
...

Indication: Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) . Has also been used in the management of bulimia nervosa .

Associated Conditions: Bulimia Nervosa, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Drug-Drug Interaction (DDI) Study for TD-9855

Phase 1

Completed

Conditions: Drug Drug Interaction (DDI)

Interventions: Drug: TD-9855
Drug: Fluvoxamine
Drug: Itraconazole
Drug: Caffeine

First Posted Date: 2018-02-14

Last Posted Date: 2021-01-14

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 41

Registration Number: NCT03432793

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-122
Drug: Fluvoxamine
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2017-11-13

Last Posted Date: 2019-01-16

Lead Sponsor: Celgene

Target Recruit Count: 81

Registration Number: NCT03340662

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

Phase 4

Conditions: Depressive Disorder

Interventions: Combination Product: fluoxetine + cognitive-behavioral treatment（CBT）
Drug: fluoxetine + Amfebutamone
Combination Product: physical treatment+fluoxetine+amfebutamone
Combination Product: Cognitive behavior treatment +fluvoxamine
Drug: Lithium+fluvoxamine
Combination Product: fluvoxamine + lithium + physical therapy
Drug: Mirtazapine/SNRIs
Combination Product: mirtazapine+ Cognitive behavior treatment
Drug: mirtazapine + SNRIs
Combination Product: mirtazapine + SNRIs + physical therapy
Other: TAU(treat as usual)
Drug: Fluoxetine
Drug: Fluvoxamine

First Posted Date: 2017-07-17

Last Posted Date: 2017-10-10

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 800

Registration Number: NCT03219008

Locations: 🇨🇳
ShanghaiMHC, Shanghai, China

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Fluvoxamine
Drug: BI 409306 - Powder for oral solution (PfOS)
Drug: BI 409306 - film coated tablet

First Posted Date: 2016-08-02

Last Posted Date: 2024-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02853136

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

First Posted Date: 2016-01-14

Last Posted Date: 2021-07-02

Lead Sponsor: University of Washington

Target Recruit Count: 635

Registration Number: NCT02655354

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Honor Health, Scottsdale, Arizona, United States

and more 21 locations

The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia

Not Applicable

Conditions: Depression

Interventions: Drug: fluvoxamine

First Posted Date: 2015-05-13

Last Posted Date: 2015-05-13

Lead Sponsor: Guang Dong Provincial Mental Health Institute

Target Recruit Count: 30

Registration Number: NCT02442713

Locations: 🇨🇳
Guangdong Provincial Mental Health Institute, Guang Zhou, Guangdong, China

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Completed

Conditions: Acute Kidney Injury
Depression

Interventions: Drug: Duloxetine
Drug: Citalopram
Drug: Escitalopram
Drug: Venlafaxine
Drug: Desvenlafaxine
Drug: Fluoxetine
Drug: Fluvoxamine
Drug: Paroxetine
Drug: Sertraline

First Posted Date: 2014-12-19

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 3255526

Registration Number: NCT02320240

Locations: 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

Phase 4

Completed

Conditions: Obsessive-Compulsive Disorder
Anxiety Disorders
Mental Disorders

Interventions: Behavioral: Exposure and Response Prevention
Drug: Fluoxetine
Drug: Sertraline
Drug: Paroxetine
Drug: Citalopram
Drug: Fluvoxamine

First Posted Date: 2013-12-30

Last Posted Date: 2022-09-09

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 78

Registration Number: NCT02022709

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy